{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:38:35Z","timestamp":1791319115858,"version":"4.3.1"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Antistaphylococcal beta-lactams enhance daptomycin activity and have been used successfully in combination for refractory methicillin-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n            (MRSA) infections. Ceftaroline possesses MRSA activity, but it is unknown if it improves the daptomycin potency comparably to other beta-lactams. We report a complex patient case of endocarditis who was treated with daptomycin in combination with ceftaroline, which resulted in clearance of a daptomycin-nonsusceptible strain. An\n            <jats:italic>in vitro<\/jats:italic>\n            pharmacokinetic\/pharmacodynamic model of renal failure was used to simulate the development of daptomycin resistance and evaluate the microbiologic effects of daptomycin plus ceftaroline treatment. Combination therapy with daptomycin and ceftaroline restored daptomycin sensitivity\n            <jats:italic>in vivo<\/jats:italic>\n            and resulted in clearance of persistent blood cultures. Daptomycin susceptibility\n            <jats:italic>in vitro<\/jats:italic>\n            was increased in the presence of either ceftaroline or oxacillin. Daptomycin at 6 mg\/kg of body weight every 48 h was bactericidal in the model but resulted in regrowth and daptomycin resistance (MIC, 2 to 4 \u03bcg\/ml) with continued monotherapy. The addition of ceftaroline at 200 mg every 12 h after the emergence of daptomycin resistance enhanced bacterial killing. Importantly, daptomycin plus ceftaroline as the initial combination therapy produced rapid and sustained bactericidal activity and prevented daptomycin resistance. Both\n            <jats:italic>in vivo<\/jats:italic>\n            - and\n            <jats:italic>in vitro<\/jats:italic>\n            -derived daptomycin resistance resulted in bacteria with more fluid cell membranes. After ceftaroline was added in the model, fluidity was restored to the level of the initial\n            <jats:italic>in vivo<\/jats:italic>\n            isolate. Daptomycin-resistant isolates required high daptomycin exposures (at least 10 mg\/kg) to optimize cell membrane damage with daptomycin alone. Ceftaroline combined with daptomycin was effective in eliminating daptomycin-resistant MRSA, and these results further justify the potential use of daptomycin plus beta-lactam therapy for these refractory infections.\n          <\/jats:p>","DOI":"10.1128\/aac.00797-12","type":"journal-article","created":{"date-parts":[[2012,8,7]],"date-time":"2012-08-07T02:49:14Z","timestamp":1344307754000},"page":"5296-5302","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":103,"title":["Addition of Ceftaroline to Daptomycin after Emergence of Daptomycin-Nonsusceptible Staphylococcus aureus during Therapy Improves Antibacterial Activity"],"prefix":"10.1128","volume":"56","author":[{"given":"Warren E.","family":"Rose","sequence":"first","affiliation":[{"name":"Pharmacy Practice Division, University of Wisconsin\u2014Madison School of Pharmacy, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas T.","family":"Schulz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Andes","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Wisconsin\u2014Madison School of Medicine and Public Health, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Striker","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Wisconsin\u2014Madison School of Medicine and Public Health, Madison, Wisconsin, USA"},{"name":"William S. Middleton Veterans Hospital, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Berti","sequence":"additional","affiliation":[{"name":"Pharmacy Practice Division, University of Wisconsin\u2014Madison School of Pharmacy, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Hutson","sequence":"additional","affiliation":[{"name":"Pharmacy Practice Division, University of Wisconsin\u2014Madison School of Pharmacy, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay K.","family":"Shukla","sequence":"additional","affiliation":[{"name":"Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.7.1925-1929.2000"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.68.6.3548-3553.2000"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00766-08"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/15.suppl_A.125"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.59.12.4332-4337.1991"},{"key":"e_1_3_1_7_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2011","unstructured":"Clinical and Laboratory Standards Institute. 2011. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 11th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"11"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir340"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq253"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.2799-2807.2004"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.122108599"},{"key":"e_1_3_1_12_2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ijantimicag.2009.12.022","article-title":"In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin\/clavulanic acid or ampicillin","volume":"35","author":"Entenza JM","year":"2010","unstructured":"EntenzaJM GiddeyM VouillamozJ MoreillonP. 2010. In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin\/clavulanic acid or ampicillin. Int. J. Antimicrob. Agents 35:451\u2013456.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks006"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr019"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00719-07"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.2.792-799.2004"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.6.527"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00680-10"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01682-08"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.2006\/003111-0"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00208-09"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.06.010"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028316"},{"key":"e_1_3_1_24_2","volume-title":"Abstr. 19th Eur. Congr. Clin. Microbiol. Infect. Dis.","author":"Riccobene T","year":"2009","unstructured":"RiccobeneT JakateA RankD ThyeD. 2009. An open-label, pharmacokinetic, safety, and tolerability study of single-dose intravenous ceftaroline in subjects with end-stage renal disdaese on intermittent haemodialysis, abstr P1455. Abstr. 19th Eur. Congr. Clin. Microbiol. Infect. Dis., European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland."},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00869-07"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm170"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05551-11"},{"key":"e_1_3_1_28_2","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/cid\/cir147","article-title":"Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus","volume":"52","author":"Saravolatz LD","year":"2011","unstructured":"SaravolatzLD SteinGE JohnsonLB. 2011. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 52:1156\u20131163.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00347-11"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05849-11"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3114-3121.2005"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00487-10"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00797-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00797-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:02:39Z","timestamp":1645480959000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00797-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1128\/AAC.00797-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.00797-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"2012-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-07-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-09-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}